RELAPSED NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis phase 2 trial tested a combination of two treatments—CD19/22 CAR-T cells (a type of immune cell therapy) and tislelizumab (a PD-1 inhibitor that helps immune cells attack cancer)—in 18 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal was to see if t…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis completed study tested a two-step approach for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by CAR-T cell therapy. The goal was to see if this combination could improve how l…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Supercharged immune cells take on tough lymphoma
Disease control CompletedThis completed Phase 2 trial tested a special type of immune cell therapy called CAR-T in 168 patients with relapsed or refractory non-Hodgkin lymphoma. The CAR-T cells were designed to recognize four different targets on cancer cells (CD19, CD20, CD22, and CD30). Patients receiv…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a common arthritis drug tame CAR-T's dangerous side effects?
Symptom relief CompletedThis phase 2 trial tested whether adding the drug anakinra (Kineret) to standard CAR-T cell therapy could prevent nerve toxicity in 15 people with relapsed or refractory non-Hodgkin lymphoma. Participants received anakinra injections for a week alongside their CAR-T infusion. The…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC